Imatinib mesylate is a selective small molecule receptor inhibitor of tyrosine kinases including c-Kit which was initially approved for the treatment of chronic myelogenous leukaemia harbouring c-Kit and BRC-ABL mutations. Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.